OS THERAPIES INCORPORATED Increase (Decrease) in Other Accounts Payable and Accrued Liabilities
OS THERAPIES INCORPORATED (OSTX) reported Increase (Decrease) in Other Accounts Payable and Accrued Liabilities of -$19.71 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $17.37K.
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$37.08K.
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-12-31 was $37.46K, a 56.56% decline year-over-year.
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $614.00.
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for fiscal 2025 was -$59.19K.
- OS THERAPIES INCORPORATED increase (decrease) in other accounts payable and accrued liabilities for fiscal 2024 was -$48.42K.
| Period end | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Other Accounts Payable and Accrued Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $17.37K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$19.71K 10-Q · filed 2026-08-14 | $17.75K derived: sum of 3 quarters · filed 2026-08-14 | $18.36K derived: sum of 4 quarters · filed 2026-08-14 |
| 2026-03-31 | -$37.08K 10-Q · filed 2026-05-18 | $375.00 derived: sum of 2 quarters · filed 2026-05-18 | $989.00 derived: sum of 3 quarters · filed 2026-05-18 | $719.00 derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-12-31 | $37.46K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | $38.07K derived: sum of 2 quarters · filed 2026-03-31 | $37.80K derived: sum of 3 quarters · filed 2026-08-14 | -$59.19K 10-K · filed 2026-03-31 |
| 2025-09-30 | $614.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $344.00 derived: sum of 2 quarters · filed 2026-08-14 | -$96.64K 10-Q · filed 2025-11-14 | -$10.41K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-06-30 | -$270.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$97.26K 10-Q · filed 2026-08-14 | -$11.03K derived: sum of 3 quarters · filed 2026-08-14 | -$114.43K derived: sum of 4 quarters · filed 2026-08-14 |
| 2025-03-31 | -$96.99K 10-Q · filed 2026-05-18 | -$10.76K derived: sum of 2 quarters · filed 2026-05-18 | -$114.16K derived: sum of 3 quarters · filed 2026-05-18 | |
| 2024-12-31 | $86.23K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-31 | -$17.18K derived: sum of 2 quarters · filed 2026-03-31 | -$48.42K 10-K · filed 2026-03-31 | |
| 2024-09-30 | -$103.41K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$134.65K 10-Q · filed 2025-11-14 | ||
| 2024-06-30 | -$31.25K 10-Q · filed 2025-08-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verrica Pharmaceuticals Inc. (VRCA) | United States | $0.076B | -3.39 |
| iBio, Inc. (IBIO) | United States | $0.077B | -2.94 |
| MAIA Biotechnology, Inc. (MAIA) | United States | $0.077B | -2.30 |
| Valion Bio, Inc. (VBIO) | United States | $0.077B | |
| Adicet Bio, Inc. (ACET) | United States | $0.078B | -0.81 |
| Lifevantage Corp (LFVN) | United States | $0.078B | 15.40 |
| Aldeyra Therapeutics, Inc. (ALDX) | United States | $0.074B | -5.57 |
| Cingulate Inc. (CING) | United States | $0.073B | -2.64 |
| Spero Therapeutics, Inc. (SPRO) | United States | $0.073B | 17.41 |
| Gain Therapeutics, Inc. (GANX) | United States | $0.080B | -4.40 |